CANC
Tema Oncology ETF
CANC is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations.
Global
EQUITY
Active
MANAGEMENT STYLE
$ 208.4 M
ASSETS UNDER MGMT
99 bp
EXPENSES
Fund Basics
| Inception date | Aug 15, 2023 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Annually |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | No |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| GENMAB A/S SPONSORED ADR | 5.7 % |
| ELI LILLY & CO | 5.3 % |
| REVOLUTION MEDICINES, INC. | 5.2 % |
| MERCK & CO. INC. | 5.2 % |
| COGENT BIOSCIENCES INC | 4.5 % |
| NOVARTIS AG | 4.2 % |
| ABBVIE INC | 4.0 % |
| HALOZYME THERAPEUTICS INC | 3.8 % |
| BEIGENE LTD. SPONSORED ADR | 3.7 % |
| EXELIXIS INC | 3.6 % |
Constituent Breakdown
| Number of holdings | 55 |
| Herfindahl-Hirschman Index | 290 |
| Wgt avg mkt cap (mns) | $154,129 |
| Large cap (>$10bn) | 60.1% |
| Mid cap ($2-10bn) | 22.3% |
| Small cap (<$2bn) | 16.4% |
| Developed mkts. | 92.4% |
| Emerging mkts. | 5.5% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 75.2 % |
 |
SWITZERLAND | 7.3 % |
 |
DENMARK | 5.7 % |
 |
CHINA | 5.4 % |
 |
BRITAIN | 3.2 % |
 |
CANADA | 1.4 % |
Historical Performance
Standardized Performance (as of 09/30/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 21.0% | 46.4% | 21.6% | 21.9% | -- | -- | -- | 131.4% |
| Dividend Yield | 0.0% | 0.1% | 1.7% | 1.4% | -- | -- | -- | 2.5% |
| Total Returns | 21.0% | 46.5% | 23.3% | 23.3% | -- | -- | -- | 133.9% | Ann. Volatility | 23.7% | 22.8% | 24.4% | 23.4% | -- | -- | -- | 404.8% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.74 | 18% |
| MSCI EAFE | 0.73 | 26% |
| MSCI Emg Mkts | 0.31 | 12% |
Liquidity Measures
| Avg. volume (000) | 19 |
| ADV traded (mns) | $1 |
| Turnover | 0.4% |
| Avg. Bid/Ask (% of price) | 0.36% |
Technical Indicators
| 30d moving avg. (EMA) | $41.51 |
| Relative strength (RSI) | 52 |
| MACD/Signal | 0.17/-0.02 |
| Bollinger Bands (Upper/Lower) | $42.95/$39.17 |
| Short interest (% of AUM) | 0.5% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. CANC |
Expenses vs. CANC |
ALTAR Score™ vs. CANC |
|---|---|---|---|---|
| HRTS | Tema Heart & Health ETF | 33.4% | 0 bp | +3.8% |
| PBPH | Portfolio Building Block World Pharma and Biotech Index ETF | 30.5% | -86 bp | +7.9% |
| FTXH | First Trust Nasdaq Pharmaceuticals ETF | 28.0% | -39 bp | +7.7% |
| IXJ | iShares Global Healthcare ETF | 25.5% | -61 bp | +7.7% |
| AGNG | Global X Aging Population ETF | 25.3% | -49 bp | +6.5% |
| JDOC | JPMorgan Healthcare Leaders ETF | 25.1% | -34 bp | +6.8% |
| MEDX | Horizon Kinetics Medical ETF | 23.7% | -14 bp | +3.2% |
| IYH | iShares U.S. Healthcare ETF | 23.5% | -62 bp | +7.3% |
| VHT | Vanguard Health Care ETF | 23.1% | -90 bp | +6.7% |
| FHLC | Fidelity MSCI Health Care Index ETF | 23.0% | -91 bp | +6.9% |
Risk and Returns: CANC vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 11/6/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
-2.0%
ALTAR SCORE™
1st
PERCENTILE
AVOID
ETFRC RATING
There are 746 funds in the Global Equity category with an average
ALTAR Score™ of 4.8% and a standard deviation
of 2.6%. CANC's ALTAR Score™ is approximately -2.6 standard
deviations above the category average. This places CANC in the 1st percentile
among funds in the category.
Sell-Side Consensus
$55.23
PRICE TARGET
+35.4%
UPSIDE
Bid/Ask Spreads
36 bp
AVG SPREAD
15 —
100 bp
RANGE